藤黄菌素-4’ -O-葡糖苷 | 6920-38-3

• 物质功能分类: 生物化工 - 提取物
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 中文名称: 藤黄菌素-4’ -O-葡糖苷
• 中文别名: 藤黄菌素-4’-O-葡糖苷；藤黄菌素-4'-O-葡糖苷；藤黄菌素-4' -O-葡糖苷
• 英文名称: luteolin-4'-O-β-D-glucopyranoside
• 英文别名: 4'-O-β-glucopyranosyl-3',5,7-trihydroxyflavone；luteolin-4’-O-β-D-glucoside；luteolin-4′-O-β-D-glucoside；quercetin-4'-O-β-D-glucopyranoside；luteolin 4'-O-β-D-glucopyraniside；luteolin 4'-O-β-D-glucopyranoside；Luteolin-4'-o-glucoside；5,7-dihydroxy-2-[3-hydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one
• CAS: 6920-38-3
• 化学式: C₂₁H₂₀O₁₁
• 分子量: 448.383
• InChiKey: UHNXUSWGOJMEFO-QNDFHXLGSA-N

物化性质

• 熔点：
  210°C (dec.)
• 沸点：
  814.5±65.0 °C(Predicted)
• 密度：
  1.713±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  186
• 氢给体数：
  7
• 氢受体数：
  11

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	luteolin 4'-O-β-D-glucopyranoside 7-O-β-D-glucopyranoside	70404-47-6	C27H30O16	610.526
  木犀草素	2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-chromen-4-on	491-70-3	C15H10O6	286.241

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  木犀草素	2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-chromen-4-on	491-70-3	C15H10O6	286.241

反应信息

• 作为反应物：
  描述：

  藤黄菌素-4’ -O-葡糖苷 生成 D-葡萄糖
  参考文献：
  名称：

  IKRAMOV, M. T.;MAVASHEVA, F. A.;BATIROV, EH. X.;MALIKOV, V. M., XIMIYA PRIROD. SOED.,(1990) N, S. 273-274

  摘要：

  DOI：
• 作为产物：
  描述：

  尿苷(5')二氢二磷酰(1)-alpha-D-葡萄糖 、 木犀草素 在 Populus deltoids Marsh PGT-3 作用下， 反应 0.5h， 生成 藤黄菌素-4’ -O-葡糖苷
  参考文献：
  名称：

  Biological synthesis of isorhamnetin 3-O-glucoside using engineered glucosyltransferase

  摘要：

  The gene for one of the glycosyltransferases from Populus deltoids, PGT-3, was cloned and was expressed as a glutathione S-transferase fusion protein in Escherichia coli. Various flavonoids were used as potential substrates of the purified recombinant PGT-3. Flavones having two adjacent hydroxyl groups were served as substrate. The regioselectivity of PGT-3 depends on the hydroxyl groups of the substrate. Flavones having two adjacent hydroxyl groups in the B ring were glucosylated at the 4'-hydroxyl group. However. PGT-3 transferred a glucose group to the 3-hydroxyl group of isorhamnetin. Molecular modeling and docking and site-directed mutagenesis were carried out to engineer a PGT-3 having a specificity for isorhamnetin but not for quercetin. Glu82Leu turned out to display this activity. Using the Glu82Leu mutant and a quercetin 3'-O-methyltransferase, isorhamnetin 3-O-glucoside was synthesized. (C) 2010 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.molcatb.2010.01.012

文献信息

• Tire with rubber containing flavone
  申请人：THE GOODYEAR TIRE & RUBBER COMPANY

  公开号：EP1391327A1

  公开（公告）日：2004-02-25

  The invention relates to a rubber composition and a pneumatic tire having a component comprising a rubber containing the reaction product of a flavone and a methylene donor.

  本发明涉及一种橡胶组合物和充气轮胎，其成分包括含有黄酮和亚甲基供体反应产物的橡胶。
• Rubber composition and tire with rubber containing flavone
  申请人：The Goodyear Tire & Rubber Company

  公开号：EP2730431A1

  公开（公告）日：2014-05-14

  A rubber composition comprising a diene based elastomer and an adhesion promoter derived from a flavone, a methylene donor and a methylene acceptor is disclosed. The rubber composition is essentially free of cobalt. Also, a pneumatic tire comprising such a rubber composition is disclosed.

  本发明公开了一种橡胶组合物，该组合物包含一种二烯基弹性体和一种由黄酮、亚甲基供体和亚甲基受体衍生的附着力促进剂。该橡胶组合物基本上不含钴。此外，还公开了一种包含这种橡胶组合物的充气轮胎。
• CHALLENGE TEST FOR DIAGNOSING SUBTYPE OF AUTISM SPECTRUM DISEASE
  申请人：Stalicla S.A.

  公开号：EP3479845A1

  公开（公告）日：2019-05-08

  The present invention is directed to a method of identifying autism spectrum disorder (ASD) subtype 1 patients, wherein the method comprises: administering an Nrf2-activator to an ASD patient previously diagnosed with ASD or a subject displaying clinical signs of ASD, and identifying the ASD patient as an ASD subtype 1 patient if the patient shows a negative response after administration of the Nrf2-activator. Likewise, the present invention is directed to an Nrf2-activator for use in identifying autism spectrum disorder (ASD) subtype 1 patients, wherein the Nrf2-activator is administered to a subject, wherein the subject is a patient previously diagnosed with ASD or a subject displaying clinical signs of ASD and wherein an ASD subtype 1 patient is identified by a negative response.

  本发明涉及一种鉴别自闭症谱系障碍（ASD）亚型1患者的方法，其中该方法包括：向先前诊断为ASD的ASD患者或显示ASD临床症状的受试者施用Nrf2-激活剂，如果患者在施用Nrf2-激活剂后显示阴性反应，则将该ASD患者鉴别为ASD亚型1患者。同样，本发明涉及一种用于鉴定自闭症谱系障碍（ASD）亚型1患者的Nrf2-激活剂，其中将Nrf2-激活剂施用给受试者，受试者是先前诊断为ASD的患者或显示ASD临床症状的受试者，并且通过阴性反应鉴定ASD亚型1患者。
• Method of identifying ASD phenotype 1 patients
  申请人：Stalicla S.A.

  公开号：US11364311B2

  公开（公告）日：2022-06-21

  The present invention is directed to a method of identifying autism spectrum disorder (ASD) phenotype 1 patients, wherein the method comprises: administering an Nrf2-activator to an ASD patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD, and identifying the ASD patient as an ASD phenotype 1 patient if the patient shows a negative response after administration of the Nrf2-activator. Likewise, the present invention is directed to a method for classifying autism spectrum disorder (ASD) phenotype 1 patients, the method comprising: administering an Nrf2-activator to a subject, and observing if the subject shows a negative response after administration of the Nrf2-activator, in which the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD and in which the negative response supports classification of the subject as an ASD phenotype 1 patient.

  本发明涉及一种鉴定自闭症谱系障碍（ASD）表型1患者的方法，其中该方法包括：给先前诊断为特发性ASD的ASD患者或显示ASD临床症状的受试者施用Nrf2-激活剂，如果患者在施用Nrf2-激活剂后显示出负反应，则将该ASD患者鉴定为ASD表型1患者。同样，本发明还涉及一种对自闭症谱系障碍（ASD）表型1患者进行分类的方法，该方法包括：给受试者施用Nrf2-激活剂，观察受试者在施用Nrf2-激活剂后是否表现出阴性反应，其中受试者是先前诊断为特发性ASD的患者或表现出ASD临床症状的受试者，阴性反应支持将受试者分类为ASD表型1患者。
• Challenge test for diagnosing subtypes of ASD
  申请人：Stalicla S.A.

  公开号：US11357871B2

  公开（公告）日：2022-06-14

  The present invention is directed to a method for differentiating between ASD phenotype 1, phenotype 2 and other ASD patients, wherein the method comprises: administering an Nrf2-activator to a subject, and identifying the subject as an ASD phenotype 1 patient if the subject shows a negative response, as a phenotype 2 patient if he shows a positive response and as another ASD patient if he does not show a positive nor a negative response, wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD. Likewise, the present invention is directed to an Nrf2-activator for use in differentiating between autism spectrum disorder (ASD) phenotype 1 patients, phenotype 2 patients and other ASD patients, wherein the Nrf2-activator is administered to a subject, wherein a phenotype 1 patient is identified by a negative response, a phenotype 2 patient is identified by a positive response and other ASD patients are identified by the absence of a positive and a negative wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD.

  本发明涉及一种用于区分ASD表型1、表型2和其他ASD患者的方法，其中该方法包括：给受试者施用Nrf2-激活剂，如果受试者表现出阴性反应，则将其鉴定为ASD表型1患者；如果受试者表现出阳性反应，则将其鉴定为表型2患者；如果受试者既未表现出阳性反应也未表现出阴性反应，则将其鉴定为其他ASD患者，其中受试者是先前被诊断为特发性ASD的患者或表现出ASD临床症状的受试者。同样，本发明涉及一种用于区分自闭症谱系障碍（ASD）表型1患者、表型2患者和其他ASD患者的Nrf2-激活剂，其中将Nrf2-激活剂施用于受试者，表型1患者通过阴性反应确定，表型2患者通过阳性反应确定，其他ASD患者通过不显示阳性和阴性反应确定，其中受试者是先前诊断为特发性ASD的患者或显示ASD临床症状的受试者。